# CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

> **NCT00333190** · NA · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Hematologic Malignancy
- AML
- ALL
- CML
- Multiple Myeloma
- NHL
- Hodgkin's Lymphoma

## Interventions

- **DEVICE:** CD+8 T cell depletion

## Key facts

- **NCT ID:** NCT00333190
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-03
- **Final completion:** 2009-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333190, "CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00333190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*